艾滋病患者合并肿瘤的研究现状
Research Status of AIDS Patients Complicated with Cancers
DOI: 10.12677/ACM.2023.132395, PDF,    科研立项经费支持
作者: 杨 靓*, 陈晓红#：哈尔滨医科大学附属第四医院感染科，黑龙江 哈尔滨
关键词: 艾滋病；艾滋病相关性肿瘤；非艾滋病相关性肿瘤；AIDS； AIDS-Related Cancers； Non-AIDS-Related Cancers
摘要: 近年来，随着高效抗反转录病毒治疗(HAART)的出现，人类免疫缺陷病毒(HIV)感染者和获得性免疫缺陷综合征(AIDS)患者的死亡率大大降低，HIV感染者的生存条件得到了有效改善，但随之而来的人口老龄化，使得HIV感染者罹患肿瘤的风险增加。HIV感染和肿瘤的双重打击使得现阶段HIV感染者的生存受到严重威胁，因此，了解艾滋病合并肿瘤的特点对提高患者的总生存率具有重要意义。该文主要对常见的艾滋病合并肿瘤进行综述，从而为早期临床筛查、诊疗提供线索。
Abstract: In recent years, with the emergence of Highly Active Anti-Retroviral Therapy (HAART), human im-munodeficiency virus (HIV) infection and the mortality rate of acquired immunodeficiency syn-drome (AIDS) patients are greatly reduced, and living conditions of HIV infection people have been greatly improved, but the risk suffering from cancer among people infected with HIV is increasing resulting from the population aging. The double blow of HIV infection and tumor has seriously threatened the survival of HIV infected people at the present stage. Therefore, understanding the characteristics of AIDS combined with tumors is of great significance to improve the overall survival rate of patients. This article mainly reviews the common tumors AIDS complicated with, so as to provide clues for clinical screening, diagnosis and treatment of them.
文章引用：杨靓, 陈晓红. 艾滋病患者合并肿瘤的研究现状[J]. 临床医学进展, 2023, 13(2): 2802-2810. https://doi.org/10.12677/ACM.2023.132395

参考文献

[1] 张维, 李奇穗, 邓长刚, 黄薇, 孙艳雨, 袁婧. 重庆地区HIV感染者和AIDS患者合并恶性肿瘤疾病谱分析[J]. 中国预防医学杂志, 2021, 22(10): 752-756.
[2] 甘清鑫, 刘晋新. 艾滋病合并恶性肿瘤[J]. 新发传染病电子杂志, 2016, 1(1): 53-55.
[3] Goncalves, P.H., Montezuma-Rusca, J.M., Yarchoan, R. and Uldrick, T.S. (2016) Cancer Pre-vention in HIV-Infected Populations. Seminars in Oncology, 43, 173-188. [Google Scholar] [CrossRef] [PubMed]
[4] Chang, Y., Cesarman, E., Pessin, M.S., et al. (1994) Identi-fication of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi’s Sarcoma. Science, 266, 1865-1869. [Google Scholar] [CrossRef] [PubMed]
[5] Dupin, N. (2020) Update on Oncogenesis and Therapy for Kaposi Sarcoma. Current Opinion in Oncology, 32, 122-128. [Google Scholar] [CrossRef] 
[6] Coscoy, L. and Ganem, D. (2000) Kaposi’s Sar-coma-Associated Herpesvirus Encodes Two Proteins That Block Cell Surface Display of MHC Class I Chains by En-hancing Their Endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 97, 8051-8056. [Google Scholar] [CrossRef] [PubMed]
[7] Coscoy, L., Sanchez, D.J. and Ganem, D. (2001) A Novel Class of Herpesvirus-Encoded Membrane-Bound E3 Ubiquitin Ligases Regulates Endocytosis of Proteins In-volved in Immune Recognition. Journal of Cell Biology, 155, 1265-1273. [Google Scholar] [CrossRef] [PubMed]
[8] Karabajakian, A., Ray-Coquard, I. and Blay, J.Y. (2022) Molecular Mechanisms of Kaposi Sarcoma Development. Cancers, 14, Article No. 1869. [Google Scholar] [CrossRef] [PubMed]
[9] Jary, A., Veyri, M., Gothland, A., et al. (2021) Kaposi’s Sar-coma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposi’s Sarcoma. Cancers, 13, Article No. 6208. [Google Scholar] [CrossRef] [PubMed]
[10] Vangipuram, R. and Tyring, S.K. (2019) AIDS-Associated Malignancies. In: Meyers, C., Ed., HIV/AIDS-Associated Viral Oncogenesis. Cancer Treatment and Research, Vol. 177, Springer, Cham, 1-21. [Google Scholar] [CrossRef] [PubMed]
[11] Royse, K.E., El Chaer, F., Amirian, E.S., et al. (2017) Dispari-ties in Kaposi Sarcoma Incidence and Survival in the United States: 2000-2013. PLOS ONE, 12, e0182750. [Google Scholar] [CrossRef] [PubMed]
[12] Jary, A., Gothland, A., Palich, R., et al. (2021) Poppers, by In-ducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men. Open Forum Infectious Diseases, 8, Article ID: ofab166. [Google Scholar] [CrossRef] [PubMed]
[13] Lodi, S., Guiguet, M., Costagliola, D., et al. (2010) Kaposi Sarcoma In-cidence and Survival among HIV-Infected Homosexual Men after HIV Seroconversion. Journal of the National Cancer Institute, 102, 784-792. [Google Scholar] [CrossRef] [PubMed]
[14] Maurer, T., Ponte, M. and Leslie, K. (2007) HIV-Associated Kaposi’s Sarcoma with a High CD4 Count and a Low Viral Load. New England Journal of Medicine, 357, 1352-1353. [Google Scholar] [CrossRef] 
[15] Schneider, J.W. and Dittmer, D.P. (2017) Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology, 18, 529-539. [Google Scholar] [CrossRef] [PubMed]
[16] Radu, O. and Pantanowitz, L. (2013) Kaposi Sarcoma. Archives of Pathology & Laboratory Medicine, 137, 289-294. [Google Scholar] [CrossRef] 
[17] Dupin, N., Jary, A., Boussouar, S., et al. (2021) Current and Fu-ture Tools for Diagnosis of Kaposi’s Sarcoma. Cancers, 13, Article No. 5927. [Google Scholar] [CrossRef] [PubMed]
[18] Grabar, S. and Costagliola, D. (2021) Epidemiology of Kaposi’s Sarcoma. Cancers, 13, Article No. 5692. [Google Scholar] [CrossRef] [PubMed]
[19] Lebbe, C., Garbe, C., Stratigos, A.J., et al. (2019) Diagnosis and Treatment of Kaposi’s Sarcoma: European Consensus-Based Interdisciplinary Guideline (EDF/EADO/EORTC). Euro-pean Journal of Cancer, 114, 117-127. [Google Scholar] [CrossRef] [PubMed]
[20] Reid, E., Suneja, G., Ambinder, R.F., et al. (2019) AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehen-sive Cancer Network, 17, 171-189. [Google Scholar] [CrossRef] 
[21] Ramaswami, R., Polizzotto, M.N., Lurain, K., et al. (2022) Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clinical Cancer Research, 28, 840-850. [Google Scholar] [CrossRef] 
[22] Reid, E.G., Shimabukuro, K.A., Moore, P., et al. (2022) AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. Clinical Cancer Research, 28, 2646-2656. [Google Scholar] [CrossRef] 
[23] Alomari, N. and Totonchy, J. (2020) Cytokine-Targeted Therapeutics for KSHV-Associated Disease. Viruses, 12, Article No. 1097. [Google Scholar] [CrossRef] [PubMed]
[24] Ngalamika, O., Mukasine, M.C., Kawimbe, M. and Vally, F. (2021) Viral and Immunological Markers of HIV-Associated Kaposi Sarcoma Recurrence. PLOS ONE, 16, e0254177. [Google Scholar] [CrossRef] [PubMed]
[25] Tuncer, S.B., Celik, B., Akdeniz Odemis, D., et al. (2022) MiRNA Sequence Analysis in Patients with Kaposi’s Sarcoma-Associated Herpesvirus. Pathology and Oncology Re-search, 28, Article ID: 1610055. [Google Scholar] [CrossRef] [PubMed]
[26] Huang, X., Rao, W., Wang, C., et al. (2022) Kaposi’s Sar-coma-Associated Herpes Virus-Derived microRNA K12-1 Over-Activates the PI3K/Akt Pathway to Facilitate Cancer Progression in HIV-Related Gastrointestinal Kaposi’s Sarcoma. SLAS Discovery, 27, 258-265. [Google Scholar] [CrossRef] [PubMed]
[27] Lee, S.M., Kaye, K.M. and Slack, F.J. (2021) Cellular mi-croRNA-127-3p Suppresses Oncogenic Herpesvirus-Induced Transformation and Tumorigenesis via Down-Regulation of SKP2. Proceedings of the National Academy of Sciences of the United States of America, 118, e2105428118. [Google Scholar] [CrossRef] [PubMed]
[28] Re, A., Cattaneo, C. and Rossi, G. (2019) HIV and Lymphoma: From Epidemiology to Clinical Management. Mediterranean Journal of Hematology and Infectious Diseases, 11, e2019004. [Google Scholar] [CrossRef] [PubMed]
[29] Epeldegui, M., Widney, D.P. and Martínez-Maza, O. (2006) Pathogenesis of AIDS Lymphoma: Role of Oncogenic Viruses and B Cell Activation-Associated Molecular Lesions. Current Opinion in Oncology, 18, 444-448. [Google Scholar] [CrossRef] [PubMed]
[30] Epeldegui, M., Vendrame, E. and Martínez-Maza, O. (2010) HIV-Associated Immune Dysfunction and Viral Infection: Role in the Pathogenesis of AIDS-Related Lymphoma. Immunologic Research, 48, 72-83. [Google Scholar] [CrossRef] [PubMed]
[31] Epeldegui, M. and Hussain, S.K. (2020) The Role of Microbial Translocation and Immune Activation in AIDS-Associated Non-Hodgkin Lymphoma Pathogenesis: What Have We Learned? Critical Reviews™ in Immunology, 40, 41-51. [Google Scholar] [CrossRef] 
[32] Dolcetti, R., Giagulli, C., He, W., et al. (2015) Role of HIV-1 Matrix Protein P17 Variants in Lymphoma Pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 112, 14331-14336. [Google Scholar] [CrossRef] [PubMed]
[33] Dolcetti, R., Gloghini, A., Caruso, A. and Carbone, A. (2016) A Lymphomagenic Role for HIV beyond Immune Suppression? Blood, 127, 1403-1409. [Google Scholar] [CrossRef] [PubMed]
[34] Caccuri, F., Muraro, E., Gloghini, A., et al. (2019) Lym-phomagenic Properties of a HIV p17 Variant Derived from a Splenic Marginal Zone Lymphoma Occurred in a HIV-Infected Patient. Hematological Oncology, 37, 176-184. [Google Scholar] [CrossRef] [PubMed]
[35] Caby, F., Guiguet, M., Weiss, L., et al. (2021) CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 73, 50-59. [Google Scholar] [CrossRef] [PubMed]
[36] 李雪芹, 潘子昂, 郑梅竹, 刘晋新, 施欲新, 王杏, 李莉, 叶雯, 胡天丽, 夏爽, 李宏军. 艾滋病合并弥漫大B细胞淋巴瘤和艾滋病合并伯基特淋巴瘤的临床影像特征[J]. 临床放射学杂志, 2020, 39(12): 2532-2536.
[37] Kesavan, M., Eyre, T.A. and Collins, G.P. (2019) Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 14, 207-218. [Google Scholar] [CrossRef] [PubMed]
[38] Navarro, J.-T., Ribera, J.-M., Oriol, A., et al. (2001) Influence of Highly Active Anti-Retroviral Therapy on Response to Treatment and Survival in Patients with Acquired Immunodefi-ciency Syndrome-Related Non-Hodgkin’s Lymphoma Treated with Cyclophosphamide, Hydroxydoxorubicin, Vincris-tine and Prednisone. British Journal of Haematology, 112, 909-915. [Google Scholar] [CrossRef] [PubMed]
[39] Vaccher, E., Spina, M., di Gennaro, G., et al. (2001) Con-comitant Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy plus Highly Active Antiretroviral Therapy in Patients with Human Immunodeficiency Virus-Related, Non-Hodgkin Lymphoma. Cancer, 91, 155-163. [Google Scholar] [CrossRef] 
[40] Tan, C.R.C., Barta, S.K., Lee, J., et al. (2018) Combination Antiretroviral Therapy Accelerates Immune Recovery in Patients with HIV-Related Lymphoma Treated with EPOCH: A Comparison within One Prospective Trial AMC034. Leukemia & Lymphoma, 59, 1851-1860. [Google Scholar] [CrossRef] [PubMed]
[41] 赵涵, 张坚生, 陈志敏, 刘波, 廖宝林, 蔡卫平, 何浩岚. 艾滋病相关非霍奇金淋巴瘤38例治疗及预后分析[J]. 肿瘤学杂志, 2020, 26(10): 902-906.
[42] Stebbing, J., Marvin, V. and Bower, M. (2004) The Evidence-Based Treatment of AIDS-Related Non-Hodgkin’s Lymphoma. Cancer Treatment Reviews, 30, 249-253. [Google Scholar] [CrossRef] [PubMed]
[43] Li, X., Pan, Z., Wang, X., et al.(2021) Prognostic Nomogram In-corporating Radiological Features for Predicting Overall Survival in Patients with AIDS-Related Non-Hodgkin Lym-phoma. Chinese Medical Journal, 135, 70-78. [Google Scholar] [CrossRef] 
[44] Bower, M., Stebbing, J., Tuthill, M., et al. (2008) Immuno-logic Recovery in Survivors Following Chemotherapy for AIDS-Related Non-Hodgkin Lymphoma. Blood, 111, 3986-3990. [Google Scholar] [CrossRef] [PubMed]
[45] Hernández-Ramírez, R.U., Shiels, M.S., Dubrow, R. and Engels, E.A. (2017) Cancer Risk in HIV-Infected People in the USA from 1996 to 2012: A Population-Based, Registry-Linkage Study. The Lancet HIV, 4, e495-e504. [Google Scholar] [CrossRef] 
[46] Shebl, F.M., Engels, E.A., Goedert, J.J. and Chaturvedi, A.K. (2010) Pulmonary Infections and Risk of Lung Cancer among Persons with AIDS. Journal of Acquired Immune Deficiency Syndromes, 55, 375-379. [Google Scholar] [CrossRef] 
[47] Smith, D.M., Salters, K.A., Eyawo, O., et al. (2004) Mortality among People Living with HIV/AIDS with Non-Small-Cell Lung Cancer in the Modern HAART Era. AIDS Care, 30, 936-942. [Google Scholar] [CrossRef] [PubMed]
[48] da Silva Neto, M.M., Brites, C. and Borges, Á.H. (2020) Cancer during HIV Infection. APMIS, 128, 121-128. [Google Scholar] [CrossRef] [PubMed]
[49] European AIDS Clinical Society (2019) European Guidelines for Treat-ment of HIV-Infected Adults in Europe.
[50] British HIV Association (2019) BHIVA Guidelines for the Routine In-vestigation and monitoring of Adult HIV-1-Positive Individuals.
https://www.bhiva.org/file/DqZbRxfzlYtLg/Monitoring-Guidelines.pdf
[51] Brazilian Ministry of Health (2018) Protocolo Clınico e Diretrizes Terap^euticas para Manejo da Infeccao pelo HIV em Adultos. (In Portu-guese)
[52] World Health Organization (2017) Consolidated Guideline on Sexual and Reproductive Health and Rights of Women Living with HIV.
https://apps.who.int/iris/bitstream/handle/10665/254885/9789241549998-eng.pdf?sequence=1
[53] Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.
[54] Yarchoan, R. and Uldrick, T.S. (2018) HIV-Associated Cancers and Related Diseases. New England Journal of Medicine, 378, 1029-1041. [Google Scholar] [CrossRef] 
[55] Lowy, D.R. and Schiller, J.T. (2006) Prophylactic Human Papillo-mavirus Vaccines. Journal of Clinical Investigation, 116, 1167-1173. [Google Scholar] [CrossRef] 
[56] Wilkin, T., Lee, J.Y., Lensing, S.Y., et al. (2010) Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men. The Journal of Infectious Diseases, 202, 1246-1253. [Google Scholar] [CrossRef] [PubMed]
[57] Castilho, J.L., Bian, A., Jenkins, C.A., et al. (2022) CD4/CD8 Ratio and Can-cer Risk among Adults with HIV. Journal of the National Cancer Institute, 114, 854-862. [Google Scholar] [CrossRef] [PubMed]
[58] Nagata, N., Nishijima, T., Niikura, R., et al. (2018) Increased Risk of Non-AIDS-Defining Cancers in Asian HIV-Infected Patients: A Long-Term Cohort Study. BMC Cancer, 18, Article No. 1066. [Google Scholar] [CrossRef] [PubMed]
[59] Chiao, E.Y., Coghill, A., Kizub, D., et al. (2021) The Effect of Non-AIDS-Defining Cancers on People Living with HIV. The Lancet Oncology, 22, e240-e253. [Google Scholar] [CrossRef] 
[60] Lascar, R.M., Lopes, A.R., Gilson, R.J., et al. (2005) Effect of HIV Infection and Antiretroviral Therapy on Hepatitis B Virus (HBV)—Specific T Cell Responses in Patients Who Have Resolved HBV Infection. The Journal of Infectious Diseases, 191, 1169-1179. [Google Scholar] [CrossRef] [PubMed]
[61] Hu, J., Liu, K. and Luo, J. (2019) HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Research and Treatment, 177, 231-250. [Google Scholar] [CrossRef] [PubMed]
[62] 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版) [J]. 协和医学杂志, 2021, 39(12): 715-735.
[63] Ye, F., Zeng, Y., Sha, J., et al. (2016) High Glucose Induces Reactivation of Latent Kaposi’s Sarcoma-Associated Herpesvirus. Jour-nal of Virology, 90, 9654-9663. [Google Scholar] [CrossRef] 
[64] Aneja, K.K. and Yuan, Y. (2017) Reac-tivation and Lytic Replication of Kaposi’s Sarcoma-Associated Herpesvirus: An Update. Frontiers in Microbiology, 8, Article No. 613. [Google Scholar] [CrossRef] [PubMed]
[65] Pettit, A.C., Giganti, M.J., Ingle, S.M., et al. (2018) Increased Non-AIDS Mortality among Persons with AIDS-Defining Events after Antiretroviral Therapy Initiation. Journal of the International AIDS Society, 21, e25031. [Google Scholar] [CrossRef] [PubMed]

为你推荐